Cerus Corporation
Compositions and methods for improved car-T cell therapies
Last updated:
Abstract:
The present invention relates to the preparation and use in recipients of CAR-T cell-derived effector cells which are modified to limit their proliferation within the recipient. This is accomplished through the introduction of adducts into the nucleic acids of CAR-T cell-derived effector cells following expansion in vitro to provide expanded and activated CAR-T cell-derived effector cells that retain immunologic function, including the expression of one ore more cytokines.
Status:
Grant
Type:
Utility
Filling date:
2 Nov 2015
Issue date:
23 Jun 2020